Revenue decreased 3.3%
Revenue changed -3.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed -3.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Net income changed -198.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Stock-based compensation changed -12.5% from the comparable as-filed period.
Capex / revenue changed +30 basis points from the comparable as-filed period.
SBC / revenue changed -6 basis points from the comparable as-filed period.
Capital expenditure changed +4.2% from the comparable as-filed period. The change ranks at the 20th percentile of 5 prior comparable changes.
Selling, general & administrative changed +3.4% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.